Literature DB >> 26318982

Safety and Efficacy of Bipolar Versus Monopolar Transurethral Resection of the Prostate in Patients with Large Prostates or Severe Lower Urinary Tract Symptoms: Post Hoc Analysis of a European Multicenter Randomized Controlled Trial.

A Skolarikos1, J Rassweiler2, J J de la Rosette3, G Alivizatos1, C Scoffone4, R M Scarpa5, M Schulze2, C Mamoulakis6.   

Abstract

PURPOSE: We compare bipolar vs monopolar transurethral prostate resection safety/secondary outcomes including efficacy in patients with large prostate volume or severe lower urinary tract symptoms.
MATERIALS AND METHODS: From July 2006 to June 2009 candidates for transurethral prostate resection were recruited at 4 centers, randomized 1:1 into monopolar/bipolar transurethral prostate resection arms and followed up to 36 months. Post hoc data analysis from patients with large prostate volume or severe lower urinary tract symptoms is presented. Patients with large prostate volume or severe lower urinary tract symptoms were defined as those with transrectal ultrasound based prostate volume greater than 80 ml or International Prostate Symptom Score greater than 19. Safety was estimated using sodium/hemoglobin changes immediately after surgery, complications during the early postoperative period (up to 6 weeks), and short-term (up to 12 months) and midterm (up to 36 months) followup. Secondary outcomes included, among others, efficacy quantified by changes in maximum urine flow rate, post-void residual urine volume and International Prostate Symptom Score compared with baseline.
RESULTS: A total of 279 patients were randomized. Post hoc analysis of data from patients with a large prostate volume or severe lower urinary tract symptoms was based on analysis A-in 62 of 279 participants (22.3%) (monopolar transurethral prostate resection 32, bipolar transurethral prostate resection 30) or analysis B-in 126 of 279 participants (45.2%) (monopolar transurethral prostate resection 57, bipolar transurethral prostate resection 69). Mean (SD) prostate volume was 108.0 (25.9) ml for monopolar transurethral prostate resection and 108.9 (23.4) ml for bipolar transurethral prostate resection (p=0.756). Mean International Prostate Symptom Score was 25.0 (4.2) for monopolar transurethral prostate resection and 25.3 (3.7) for bipolar transurethral prostate resection (p=0.402). Neither safety nor any secondary outcome differed significantly between the arms throughout followup. The only exception was the decrease in sodium (analysis A), which was significantly greater after monopolar transurethral prostate resection (-4.2 vs -0.7 mmol/l, p=0.023) and did not translate into a significant difference in transurethral resection syndrome rates (monopolar transurethral prostate resection 1 of 32 vs bipolar transurethral prostate resection 0 of 30, p=1.000).
CONCLUSIONS: Bipolar and monopolar transurethral prostate resection show similar safety/efficacy in these patient subpopulations.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  prostate; prostatic hyperplasia; randomized controlled trial; transurethral resection of prostate; treatment outcome

Mesh:

Year:  2015        PMID: 26318982     DOI: 10.1016/j.juro.2015.08.083

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis.

Authors:  Bernd Rosenhammer; Eva M Lausenmeyer; Roman Mayr; Maximilian Burger; Christian Eichelberg
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

Review 2.  Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate.

Authors:  Soo Jeong Kim; Omar Al Hussein Alawamlh; Bilal Chughtai; Richard K Lee
Journal:  Curr Urol Rep       Date:  2018-08-20       Impact factor: 3.092

3.  [Transurethral resection of the prostate].

Authors:  C Füllhase
Journal:  Urologe A       Date:  2016-11       Impact factor: 0.639

Review 4.  A Review Comparing Experience and Results with Bipolar Versus Monopolar Resection for Treatment of Bladder Tumors.

Authors:  Yasser Osman; Ahmed M Harraz
Journal:  Curr Urol Rep       Date:  2016-03       Impact factor: 3.092

Review 5.  [Anastomosis stenosis after radical prostatectomy and bladder neck stenosis after benign prostate hyperplasia treatment: reconstructive options].

Authors:  C M Rosenbaum; B Becker; A Gross; C Netsch
Journal:  Urologe A       Date:  2020-04       Impact factor: 0.639

6.  BPH treatment: laser for everyone | Opinion: YES.

Authors:  Carlos A R Sacomani; Ricardo Vita Nunes
Journal:  Int Braz J Urol       Date:  2018 Mar-Apr       Impact factor: 1.541

7.  Secondary hemorrhage after bipolar transurethral resection and vaporization of prostate.

Authors:  Chi-Hang Yee; Joseph Hon-Ming Wong; Peter Ka-Fung Chiu; Jeremy Yuen-Chun Teoh; Chi-Kwok Chan; Eddie Shu-Yin Chan; See-Ming Hou; Chi-Fai Ng
Journal:  Urol Ann       Date:  2016 Oct-Dec

8.  Low-pressure monopolar electroresection of the prostate for glands sized > 70 vs. < 70 cc performed with continuous irrigation and suprapubic suction: perioperative and long-term outcome.

Authors:  Konrad Wilhelm; Ioana Maria Cazana; Martin Schoenthaler; Arndt Katzenwadel; Johannes Spaeth; Arkadiusz Miernik
Journal:  World J Urol       Date:  2018-01-06       Impact factor: 4.226

9.  Bladder Neck Contracture after Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia Treated with a Thermo-Expandable Metal Stent (Memokath® 045).

Authors:  Jan Wen; Bettina Nørby; Palle Jörn Sloth Osther
Journal:  Case Rep Urol       Date:  2018-05-09

10.  Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction.

Authors:  Cameron Edwin Alexander; Malo Mf Scullion; Muhammad Imran Omar; Yuhong Yuan; Charalampos Mamoulakis; James Mo N'Dow; Changhao Chen; Thomas Bl Lam
Journal:  Cochrane Database Syst Rev       Date:  2019-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.